Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma

Lise Hoejberg, Lars Bastholt, Julia S Johansen, Ib Jarle Christensen, Julie Gehl, Henrik Schmidt

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Interleukin-6 (IL-6) is an immunomodulatory cytokine produced by both normal cells and tumor cells, including melanoma cells. The specific biological function of IL-6 in melanoma is unknown. The present study examined whether the serum concentration of IL-6 can predict prognosis in patients with metastatic melanoma. IL-6 was measured by ELISA in serum samples from 103 patients with metastatic melanoma obtained before IL-2-based immunotherapy. Patients with metastatic melanoma had higher serum IL-6 than healthy individuals (median 3.4 ng/l, range 0.3-93 ng/l vs. median 1.4 ng/l, range 0.25-22.5 ng/l, P
OriginalsprogEngelsk
TidsskriftMelanoma Research
Vol/bind22
Udgave nummer4
Sider (fra-til)287-93
Antal sider7
ISSN0960-8931
DOI
StatusUdgivet - 2012

Fingeraftryk

Melanoma
Interleukin-6
Serum
Interleukin-2
Neoplasms

Citer dette

Hoejberg, Lise ; Bastholt, Lars ; Johansen, Julia S ; Christensen, Ib Jarle ; Gehl, Julie ; Schmidt, Henrik. / Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. I: Melanoma Research. 2012 ; Bind 22, Nr. 4. s. 287-93.
@article{2bdc0b1753b24a2a9467de1ce8448274,
title = "Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma",
abstract = "Interleukin-6 (IL-6) is an immunomodulatory cytokine produced by both normal cells and tumor cells, including melanoma cells. The specific biological function of IL-6 in melanoma is unknown. The present study examined whether the serum concentration of IL-6 can predict prognosis in patients with metastatic melanoma. IL-6 was measured by ELISA in serum samples from 103 patients with metastatic melanoma obtained before IL-2-based immunotherapy. Patients with metastatic melanoma had higher serum IL-6 than healthy individuals (median 3.4 ng/l, range 0.3-93 ng/l vs. median 1.4 ng/l, range 0.25-22.5 ng/l, P",
keywords = "Adult, Aged, Female, Humans, Interleukin-6, L-Lactate Dehydrogenase, Male, Melanoma, Middle Aged, Prognosis, Skin Neoplasms, Tumor Markers, Biological",
author = "Lise Hoejberg and Lars Bastholt and Johansen, {Julia S} and Christensen, {Ib Jarle} and Julie Gehl and Henrik Schmidt",
year = "2012",
doi = "10.1097/CMR.0b013e3283550aa5",
language = "English",
volume = "22",
pages = "287--93",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams & Wilkins, Ltd.",
number = "4",

}

Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. / Hoejberg, Lise; Bastholt, Lars; Johansen, Julia S; Christensen, Ib Jarle; Gehl, Julie; Schmidt, Henrik.

I: Melanoma Research, Bind 22, Nr. 4, 2012, s. 287-93.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma

AU - Hoejberg, Lise

AU - Bastholt, Lars

AU - Johansen, Julia S

AU - Christensen, Ib Jarle

AU - Gehl, Julie

AU - Schmidt, Henrik

PY - 2012

Y1 - 2012

N2 - Interleukin-6 (IL-6) is an immunomodulatory cytokine produced by both normal cells and tumor cells, including melanoma cells. The specific biological function of IL-6 in melanoma is unknown. The present study examined whether the serum concentration of IL-6 can predict prognosis in patients with metastatic melanoma. IL-6 was measured by ELISA in serum samples from 103 patients with metastatic melanoma obtained before IL-2-based immunotherapy. Patients with metastatic melanoma had higher serum IL-6 than healthy individuals (median 3.4 ng/l, range 0.3-93 ng/l vs. median 1.4 ng/l, range 0.25-22.5 ng/l, P

AB - Interleukin-6 (IL-6) is an immunomodulatory cytokine produced by both normal cells and tumor cells, including melanoma cells. The specific biological function of IL-6 in melanoma is unknown. The present study examined whether the serum concentration of IL-6 can predict prognosis in patients with metastatic melanoma. IL-6 was measured by ELISA in serum samples from 103 patients with metastatic melanoma obtained before IL-2-based immunotherapy. Patients with metastatic melanoma had higher serum IL-6 than healthy individuals (median 3.4 ng/l, range 0.3-93 ng/l vs. median 1.4 ng/l, range 0.25-22.5 ng/l, P

KW - Adult

KW - Aged

KW - Female

KW - Humans

KW - Interleukin-6

KW - L-Lactate Dehydrogenase

KW - Male

KW - Melanoma

KW - Middle Aged

KW - Prognosis

KW - Skin Neoplasms

KW - Tumor Markers, Biological

U2 - 10.1097/CMR.0b013e3283550aa5

DO - 10.1097/CMR.0b013e3283550aa5

M3 - Journal article

VL - 22

SP - 287

EP - 293

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 4

ER -